Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.
Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, Ortiz A, Kloiber S, Wang W, Rosenblat JD, Mulsant BH
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (0)
No references identified in the available metadata. This does not establish that none exist.
Cited by — these papers cite this paper (6)
- Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review 2026-07-26 · Expand citations
- Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review 2026-07-01 · Expand citations
- Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations 2026-06-01 · Expand citations
- Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia 2026-04-24 · Expand citations
- Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats 2025-12-16 · Expand citations
- The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? 2025-08-07 · Expand citations